Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × pembrolizumab × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 73 Parkinson Disease 4, Autosomal Dominant Lewy Body 30 Melanoma 29 Lung Neoplasms 29 Squamous Cell Carcinoma of Head and Neck 26 Triple Negative Breast Neoplasms 20 Neoplasms 19 Colorectal Neoplasms 18 Breast Neoplasms 18 Neoplasm Metastasis 16 Carcinoma, Transitional Cell 14 Ovarian Neoplasms 13 Endometrial Neoplasms 13 Carcinoma 12 Stomach Neoplasms 11 Carcinoma, Renal Cell 11 Esophageal Neoplasms 10 Uterine Cervical Neoplasms 9 Urinary Bladder Neoplasms 9 Pancreatic Neoplasms 9 Esophageal Squamous Cell Carcinoma 7 Recurrence 6 Small Cell Lung Carcinoma 5 Mouth Neoplasms 5 Laryngeal Neoplasms 5 Head and Neck Neoplasms 5 Colonic Neoplasms 5 Cholangiocarcinoma 5 Skin Neoplasms 4 Rectal Neoplasms 4

Interventions

cabozantinib 1 belinostat 1 atezolizumab 1 Positron Emission Tomography Computed Tomography 1 Nivolumab 1 Magnetic Resonance Imaging 1 Ipilimumab 1 Immunoglobulin G 1 Etoposide 1 Disulfides 1 Cisplatin 1 CTLA-4 Antigen 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡